The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Open accessAbstract
BACKGROUND: Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. METHODS: We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status. The tumors originated in the pancreas, midgut, or hindgut or were of unknown origin. Patients were randomly assigned to receive an extended-release aqueous-gel formulation of lanreotide (Autogel [known in the United States as Depot], Ipsen) at a dose of 120 mg (101 patients) or placebo (103 patients) once every 28 days for 96 weeks. The primary end point was progression-free survival, defined as the time to disease progression (according to the Response Evaluation Criteria in Solid Tumors, version 1.0) or death. Secondary end points included overall survival, quality of life (assessed with the European Organization for Research and Treatment of Cancer questionnaires QLQ-C30 and QLQ-GI.NET21), and safety. RESULTS: Most patients (96%) had no tumor progression in the 3 to 6 months before randomization, and 33% had hepatic tumor volumes greater than 25%. Lanreotide, as compared with placebo, was associated with significantly prolonged progression-free survival (median not reached vs. median of 18.0 months, P<0.001 by the stratified log-rank test; hazard ratio for progression or death, 0.47; 95% confidence interval [CI], 0.30 to 0.73). The estimated rates of progression-free survival at 24 months were 65.1% (95% CI, 54.0 to 74.1) in the lanreotide group and 33.0% (95% CI, 23.0 to 43.3) in the placebo group. The therapeutic effect in predefined subgroups was generally consistent with that in the overall population, with the exception of small subgroups in which confidence intervals were wide. There were no significant between-group differences in quality of life or overall survival. The most common treatment-related adverse event was diarrhea (in 26% of the patients in the lanreotide group and 9% of those in the placebo group). CONCLUSIONS: Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%). (Funded by Ipsen; CLARINET ClinicalTrials.gov number, NCT00353496; EudraCT 2005-004904-35.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
WHO Classification of Tumours of the Digestive System
Bosman, F. T. (2010) · Medical Entomology and Zoology · Cited by 5,041
Yao, J. C., Hassan, M., Phan, A., Dagohoy, C., Leary, C., Mares, J. E., Abdalla, E. K., Fleming, J. B., Vauthey, J.-N., Rashid, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4377 · Cited by 4,510
Self-citationEverolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Self-citationSunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Self-citationRinke, A., Müller, H.-H., Schade-Brittinger, C., Klose, K.-J., Barth, P., Wied, M., Mayer, C., Aminossadati, B., Pape, U.-F., Bläker, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8510 · Cited by 2,508
Pavel, M. E., Hainsworth, J. D., Baudin, E., Peeters, M., Hörsch, D., Winkler, R. E., Klimovsky, J., Lebwohl, D., Jehl, V., Wolin, E. M., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61742-x · Cited by 1,058
Self-citationPavel, M., Baudin, E., Couvelard, A., Krenning, E., Öberg, K., Steinmüller, T., Anlauf, M., Wiedenmann, B., & Salazar, R. (2012) · Neuroendocrinology · doi:10.1159/000335597 · Cited by 873
Self-citationKouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., & Yao, J. C. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.04.024 · Cited by 607
Cited by
Dasari, A., Shen, C., Halperin, D., Zhao, B., Zhou, S., Xu, Y., Shih, T., & Yao, J. C. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0589 · Cited by 3,447
Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors
Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Yao, J. C., Fazio, N., Singh, S., Buzzoni, R., Carnaghi, C., Wolin, E., Tomasek, J., Raderer, M., Lahner, H., Voi, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00817-x · Cited by 1,292
Self-citationPavel, M., Öberg, K., Falconi, M., Krenning, E. P., Sundin, A., Perren, A., & Berruti, A. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.304 · Cited by 1,179
Self-citationPavel, M., O''Toole, D., Costa, F., Capdevila, J., Gross, D., Kianmanesh, R., Krenning, E., Knigge, U., Salazar, R., Pape, U.-F., et al. (2016) · Neuroendocrinology · doi:10.1159/000443167 · Cited by 1,041
Self-citationBrabander, T., van der Zwan, W. A., Teunissen, J. J. M., Kam, B. L. R., Feelders, R. A., de Herder, W. W., van Eijck, C. H. J., Franssen, G. J. H., Krenning, E. P., & Kwekkeboom, D. J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2743 · Cited by 614
Gastroenteropancreatic Neuroendocrine Tumors
Cives, M., & Strosberg, J. R. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21493 · Cited by 586
Strosberg, J. R., Caplin, M. E., Kunz, P. L., Ruszniewski, P. B., Bodei, L., Hendifar, A., Mittra, E., Wolin, E. M., Yao, J. C., Pavel, M. E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00572-6 · Cited by 578
Self-citationPersonalized Management of Pheochromocytoma and Paraganglioma
Nölting, S., Bechmann, N., Taieb, D., Beuschlein, F., Fassnacht, M., Kroiss, M., Eisenhofer, G., Grossman, A., & Pacak, K. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab019 · Cited by 417
Howe, J. R., Merchant, N. B., Conrad, C., Keutgen, X. M., Hallet, J., Drebin, J. A., Minter, R. M., Lairmore, T. C., Tseng, J. F., Zeh, H. J., et al. (2020) · Pancreas · doi:10.1097/mpa.0000000000001454 · Cited by 396
Strosberg, J., Wolin, E., Chasen, B., Kulke, M., Bushnell, D., Caplin, M., Baum, R. P., Kunz, P., Hobday, T., Hendifar, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5865 · Cited by 390
Self-citationSingh, S., Halperin, D., Myrehaug, S., Herrmann, K., Pavel, M., Kunz, P. L., Chasen, B., Tafuto, S., Lastoria, S., Capdevila, J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00701-3 · Cited by 386
Self-citationRinke, A., Wittenberg, M., Schade-Brittinger, C., Aminossadati, B., Ronicke, E., Gress, T. M., Müller, H.-H., Arnold, R., & for the PROMID Study Group (2017) · Neuroendocrinology · doi:10.1159/000443612 · Cited by 377
Howe, J. R., Cardona, K., Fraker, D. L., Kebebew, E., Untch, B. R., Wang, Y.-Z., Law, C. H., Liu, E. H., Kim, M. K., Menda, Y., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000846 · Cited by 376
NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018
Shah, M. H., Goldner, W. S., Halfdanarson, T. R., Bergsland, E., Berlin, J. D., Halperin, D., Chan, J., Kulke, M. H., Benson, A. B., Blaszkowsky, L. S., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0056 · Cited by 375
Strosberg, J. R., Halfdanarson, T. R., Bellizzi, A. M., Chan, J. A., Dillon, J. S., Heaney, A. P., Kunz, P. L., O’Dorisio, T. M., Salem, R., Segelov, E., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000850 · Cited by 373
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
Neuroendocrine Tumors, Version 1.2015
Kulke, M. H., Shah, M. H., Benson, A. B., Bergsland, E., Berlin, J. D., Blaszkowsky, L. S., Emerson, L., Engstrom, P. F., Fanta, P., Giordano, T., et al. (2015) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2015.0011 · Cited by 360
New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification
Crona, J., Taïeb, D., & Pacak, K. (2017) · Endocrine Reviews · doi:10.1210/er.2017-00062 · Cited by 324
Janssen, I., Blanchet, E. M., Adams, K., Chen, C. C., Millo, C. M., Herscovitch, P., Taieb, D., Kebebew, E., Lehnert, H., Fojo, A. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2751 · Cited by 276
Somatostatin Analogs in Clinical Practice: A Review
Gomes-Porras, M., Cárdenas-Salas, J., & Álvarez-Escolá, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051682 · Cited by 264
Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors
Davar, J., Connolly, H. M., Caplin, M. E., Pavel, M., Zacks, J., Bhattacharyya, S., Cuthbertson, D. J., Dobson, R., Grozinsky-Glasberg, S., Steeds, R. P., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.12.030 · Cited by 261
Self-citationKos‐Kudła, B., Castaño, J. P., Denecke, T., Grande, E., Kjaer, A., Koumarianou, A., de Mestier, L., Partelli, S., Perren, A., Stättner, S., et al. (2023) · Journal of Neuroendocrinology · doi:10.1111/jne.13343 · Cited by 256
Günther, T., Tulipano, G., Dournaud, P., Bousquet, C., Csaba, Z., Kreienkamp, H.-J., Lupp, A., Korbonits, M., Castaño, J. P., Wester, H.-J., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015388 · Cited by 253
Diabetes and Cancer: Risk, Challenges, Management and Outcomes
Shahid, R. K., Ahmed, S., Le, D., & Yadav, S. (2021) · Cancers · doi:10.3390/cancers13225735 · Cited by 187
177 Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Das, S., Al-Toubah, T., El-Haddad, G., & Strosberg, J. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1685381 · Cited by 135
“or those with hormonal over-production leading to syndromes, long-acting somatostatin agonists (SSAs) have been the cornerstone of first-line therapy [4,5].”
Reidy-Lagunes, D., Pandit-Taskar, N., O'Donoghue, J. A., Krebs, S., Staton, K. D., Lyashchenko, S. K., Lewis, J. S., Raj, N., Gönen, M., Lohrmann, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1026 · Cited by 112
Cives, M., Kunz, P. L., Morse, B., Coppola, D., Schell, M. J., Campos, T., Nguyen, P. T., Nandoskar, P., Khandelwal, V, & Strosberg, J. R. (2015) · Endocrine-Related Cancer · doi:10.1530/erc-14-0360 · Cited by 96
Approach to the Patient: Insulinoma
Hofland, J., Refardt, J. C., Feelders, R. A., Christ, E., & de Herder, W. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad641 · Cited by 91
Klomp, M. J., Dalm, S. U., de Jong, M., Feelders, R. A., Hofland, J., & Hofland, L. J. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09607-z · Cited by 69
Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives
Modica, R., Liccardi, A., Minotta, R., Cannavale, G., Benevento, E., & Colao, A. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099840 · Cited by 37
Rastogi, V., Singh, D., Mazza, J. J., Parajuli, D., & Yale, S. H. (2018) · Clinical Medicine & Research · doi:10.3121/cmr.2017.1379a · Cited by 32
Loharkar, S., & Basu, S. (2023) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2023.2211090 · Cited by 16
Yang, K., Li, J., Cheng, Y., & Bai, C. (2023) · Endocrine Connections · doi:10.1530/ec-22-0441 · Cited by 4
Janson, E. T., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., Ladekarl, M., Langer, S. W., Mortensen, J., Schalin-Jäntti, C., et al. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.941999
Metadata
- Authors
- Caplin, M. E., Pavel, M., Ćwikła, J. B., Phan, A. T., Raderer, M., Sedláčková, E., Cadiot, G., Wolin, E. M., Capdevila, J., Wall, L., Rindi, G., Langley, A., Martinez, S., Blumberg, J., & Ruszniewski, P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-17
- Volume
- 371
- Issue
- 3
- Pages
- 224-233
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2135049144
- Cited by
- 1,935
- References
- 19
- FWCI
- 110.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.